Dose relationship between GnRH antagonists and pituitary suppression.
暂无分享,去创建一个
J. Rizo | L. Gierasch | A. Hagler | S. Lahrichi | W. Vale | J. Rivier | C. Rivier | J. Porter | A. Corrigan | S. Koerber | G. Jiang
[1] G R Marshall,et al. Conformation-function relationships in LHRH analogs. I. Conformations of LHRH peptide backbone. , 2009, International journal of peptide & protein research.
[2] G R Marshall,et al. Conformation-function relationships in LHRH analogs. II. Conformations of LHRH peptide agonists and antagonists. , 2009, International journal of peptide and protein research.
[3] K. Kopple. Nitroxyl-induced T1 relaxation rates as a probe of conformation in peptide hormones. , 2009, International journal of peptide and protein research.
[4] J. Rivier,et al. Betidamino acids: versatile and constrained scaffolds for drug discovery. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[5] K. Kubo,et al. Non-peptide Angiotensin II Receptor Antagonists , 1995 .
[6] W. Vale,et al. Gonadotropin-releasing hormone antagonists: novel members of the azaline B family. , 1995, Journal of medicinal chemistry.
[7] T. Kirchner,et al. Potent pituitary-gonadal axis suppression and extremely low anaphylactoid activity of a new gonadotropin releasing hormone (GnRH) receptor antagonist "azaline B". , 1995, Biochemical pharmacology.
[8] I. A. Bergqvist. Hormonal regulation of endometriosis and the rationales and effects of gonadotrophin-releasing hormone agonist treatment: a review. , 1995, Human reproduction.
[9] A. Schally,et al. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75). , 1994, European journal of endocrinology.
[10] B. E. Evans,et al. Development of 1,4-benzodiazepine cholecystokinin type B antagonists. , 1993, Journal of medicinal chemistry.
[11] W. Greenlee,et al. Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles. , 1993, Journal of medicinal chemistry.
[12] W. Greenlee,et al. Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides. , 1993, Journal of medicinal chemistry.
[13] B. E. Evans,et al. Nanomolar-affinity, non-peptide oxytocin receptor antagonists. , 1993, Journal of medicinal chemistry.
[14] J. Rizo,et al. Conformational analysis of a highly potent dicyclic gonadotropin-releasing hormone antagonist by nuclear magnetic resonance and molecular dynamics. , 1993, Journal of medicinal chemistry.
[15] W. Vale,et al. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist * † , 1993 .
[16] A. Matsumoto,et al. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. , 1993, The Journal of clinical endocrinology and metabolism.
[17] B. Badet,et al. An α-aminoglycine derivative suitable for solid phase peptide synthesis using Fmoc strategy. , 1993 .
[18] J. Udupa,et al. New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist. , 1993, The Journal of clinical endocrinology and metabolism.
[19] D. Salunke,et al. A novel computer modeling approach to the structures of small bioactive peptides: The structure of gonadotropin releasing hormone , 1993, Proteins.
[20] M. R. Holst,et al. The effect of NMeTyr5 substitution in luteinizing hormone-releasing hormone antagonists. , 1993, Journal of medicinal chemistry.
[21] B. E. Evans,et al. Orally active, nonpeptide oxytocin antagonists. , 1992, Journal of medicinal chemistry.
[22] W. Vale,et al. Abrogation by a potent gonadotropin-releasing hormone antagonist of the estrogen/progesterone-stimulated surge-like release of luteinizing hormone and follicle-stimulating hormone in postmenopausal women. , 1992, The Journal of clinical endocrinology and metabolism.
[23] J. Lowe,et al. The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst. , 1992, Journal of medicinal chemistry.
[24] J. Rizo,et al. Conformational analysis of a highly potent, constrained gonadotropin-releasing hormone antagonist. 2. Molecular dynamics simulations , 1992 .
[25] J. Rizo,et al. Conformational analysis of a highly potent, constrained gonadotropin-releasing hormone antagonist. 1. Nuclear magnetic resonance , 1992 .
[26] M. Sauer,et al. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. , 1991, American journal of obstetrics and gynecology.
[27] W. Vale,et al. Novel gonadotropin-releasing hormone antagonists: peptides incorporating modified N omega-cyanoguanidino moieties. , 1991, Journal of medicinal chemistry.
[28] W. Crowley,et al. Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human. , 1991, The Journal of clinical endocrinology and metabolism.
[29] D. Hahn,et al. Gonadotropin releasing hormone antagonists: novel structures incorporating N omega-cyano modified guanidine moieties. , 1991, Biochemical and biophysical research communications.
[30] W. Vale,et al. The induction of premature luteolysis in normal women--follicular phase luteinizing hormone secretion and corpus luteum function in the subsequent cycle. , 1991, American journal of obstetrics and gynecology.
[31] J. Rivier,et al. General method for incorporation of modified N.omega.-cyanoguanidino moieties on selected amino functions during solid-phase peptide synthesis , 1990 .
[32] W. Vale,et al. Hormonal responses to a potent gonadotropin hormone-releasing hormone antagonist in normal elderly men. , 1990, The Journal of clinical endocrinology and metabolism.
[33] R. Sergott,et al. Inhibition of follicle-stimulating hormone secretion from gonadotroph adenomas by repetitive administration of a gonadotropin-releasing hormone antagonist. , 1990, The Journal of clinical endocrinology and metabolism.
[34] J D Veldhuis,et al. Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men. , 1990, The Journal of clinical endocrinology and metabolism.
[35] A. Katritzky,et al. Benzotriazole-assisted synthesis of monoacyl aminals and their peptide derivatives , 1990 .
[36] E. Bush,et al. LH-RH antagonists: design and synthesis of a novel series of peptidomimetics. , 1989, Journal of medicinal chemistry.
[37] C. Bowers,et al. Antide and related antagonists of luteinizing hormone release with long action and oral activity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[38] C. Bowers,et al. Design, synthesis and bioassays of antagonists of LHRH which have high antiovulatory activity and release negligible histamine. , 1987, Biochemical and biophysical research communications.
[39] W. Vale,et al. New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. , 1986, Journal of medicinal chemistry.
[40] S. Srivastava,et al. Molecular conformation of gonadoliberin using two-dimensional NMR spectroscopy. , 1986, European journal of biochemistry.
[41] T. Fielder,et al. Hormonal effects of ketoconazole in vivo in the male rat: mechanism of action. , 1986, Endocrinology.
[42] D. Veber,et al. Bioactive conformation of luteinizing hormone-releasing hormone: evidence from a conformationally constrained analog. , 1980, Science.
[43] F. Momany,et al. On the conformation of luteinizing hormone-releasing hormone, nuclear Overhauser observations. , 1979, Biochemical and biophysical research communications.
[44] A. Tonelli. The effects of isolated N‐methylated residues on the conformational characteristics of polypeptides , 1976, Biopolymers.
[45] Momany Fa,et al. Conformational energy analysis of the molecule, luteinizing hormone-releasing hormone. I. Native decapeptide. , 1976 .
[46] F. Momany. Conformational energy analysis of the molecule, luteinizing hormone-releasing hormone. 2. Tetrapeptide and decapeptide analogues. , 1976, Journal of the American Chemical Society.
[47] G. C. Levy,et al. Conformational flexibility of luteinizing hormone-releasing hormone in aqueous solution. A carbon-13 spin-lattice relaxation time study. , 1975, Biochemistry.
[48] N. Ling,et al. Analogs of luteinizing hormone releasing factor (LRF) synthesis and biological activity of [(Nα-Me)Leu7]LRF and [D-Ala6,(Nα-Me)Leu7]LRF , 1975 .
[49] P. L. Wessels,et al. High resolution nuclear magnetic resonance studies of the conformation of luteinizing hormone releasing hormone (LH-RH) and its component peptides , 1973 .
[50] W. Vale,et al. Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. , 1973, Biochemistry.
[51] G. N. Ramachandran,et al. Conformation of the LL and LD hairpin bends with internal hydrogen bonds in proteins and peptides. , 1973, Biochimica et biophysica acta.
[52] E. R. Andrew,et al. Nuclear Magnetic Resonance , 1955 .
[53] B. Lunenfeld. GnRH analogues : the state of the art 2001 : a summary of the 6th International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, February 2001 , 1996 .
[54] B. E. Evans,et al. Orally active, non-peptide oxytocin antagonists , 1994 .
[55] Marvin J. Karten,et al. An Overview of GnRH Antagonist Development: Two Decades of Progress , 1992 .
[56] W. Vale,et al. Clinical Pharmacology of LHRH Antagonists , 1990 .
[57] C. Bowers,et al. Antagonists of LHRH superior to antide ; effective sequence/activity relationships , 1990 .
[58] P. Bouchard. Recent progress on GnRH and gonadal peptides , 1990 .
[59] A. Hagler,et al. DESIGN, COMPUTER DERIVED STRUCTURE AND BIOLOGICAL ACTIVITY OF THREE BICYCLIC GONADOTROPIN RELEASING HORMONE (GnRH) ANTAGONISTS , 1990 .
[60] B. E. Evans,et al. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. , 1989, Journal of medicinal chemistry.
[61] A. Katritzky,et al. Benzotriazole-assisted synthesis of monoacyl α-aminoglycines , 1989 .
[62] D. Coy,et al. In Vitro Histamine Release with LHRH Analogs , 1987 .